Company Overview - RXO is expected to report a year-over-year decline in earnings, with a projected loss of $0.04 per share, reflecting a change of -166.7% compared to the previous year [3] - Revenues for RXO are anticipated to be $1.48 billion, down 11.1% from the same quarter last year [3] Earnings Estimates and Revisions - The consensus EPS estimate for RXO has been revised 4.76% higher in the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for RXO is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +13.86% [12] Earnings Surprise Prediction - A positive Earnings ESP reading suggests a potential earnings beat, particularly when combined with a strong Zacks Rank [10] - RXO currently holds a Zacks Rank of 4, which complicates the prediction of an earnings beat despite the positive Earnings ESP [12] Historical Performance - In the last reported quarter, RXO was expected to post earnings of $0.03 per share but only achieved $0.01, resulting in a surprise of -66.67% [13] - Over the past four quarters, RXO has only beaten consensus EPS estimates once [14] Industry Context - In the Zacks Transportation - Services industry, Hub Group is expected to report earnings of $0.44 per share, reflecting a year-over-year change of -8.3% [18] - Hub Group's revenue is projected to be $913.41 million, down 6.2% from the previous year [19]

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Piper Sandler Companies (PIPR) despite higher revenues, with a focus on how actual results compare to estimates impacting stock price [1][2]. Earnings Expectations - Piper Sandler is expected to report quarterly earnings of $4.72 per share, reflecting a year-over-year decrease of 1.7%, while revenues are projected to be $515.4 million, an increase of 3.4% from the previous year [3]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analysts' assessments [4]. Earnings Surprise Prediction - The Zacks Earnings ESP for Piper Sandler is +1.06%, suggesting analysts have recently become more optimistic about the company's earnings prospects [12]. - The stock holds a Zacks Rank of 3, indicating a neutral outlook, but the positive Earnings ESP suggests a likelihood of beating the consensus EPS estimate [12]. Historical Performance - Piper Sandler has consistently beaten consensus EPS estimates in the last four quarters, with a notable surprise of +29.05% in the last reported quarter [13][14]. Industry Context - In the broader financial investment banking sector, Evercore (EVR) is expected to report earnings of $3.83 per share, a year-over-year increase of 12.3%, with revenues projected at $1.06 billion, up 8.3% from the previous year [18]. - Evercore's consensus EPS estimate has been revised up by 2.4% over the last 30 days, with an Earnings ESP of +0.08%, indicating a likelihood of beating the consensus EPS estimate [19].

Core Viewpoint - Merck is expected to report its Q4 and full-year 2025 earnings on February 3, with a consensus estimate of $16.19 billion in sales and $2.04 per share in earnings, but earnings estimates for 2026 have declined significantly due to costs from recent M&A activities [1][7][34] Financial Performance - Merck has consistently exceeded earnings expectations in the past four quarters, with an average earnings surprise of 5.08% and a notable 9.32% surprise in the last quarter [3][34] - The company currently has an Earnings ESP of +0.33% and a Zacks Rank of 4 (Sell) [4] Factors Influencing Upcoming Results - Q4 growth is anticipated from Keytruda, Animal Health, and new drugs, although this may be offset by weaker performance from Gardasil and M&A-related costs [7][34] - Keytruda sales are projected to reach $8.31 billion, driven by strong uptake in early-stage indications and metastatic indications [9][34] - The HPV vaccine Gardasil is expected to see lower sales, particularly in China and Japan, with estimates at $1.04 billion [13][34] - The Animal Health segment is estimated to generate $1.48 billion, with mixed performance in livestock and companion animal products [17][34] Strategic Initiatives - Merck has been active in acquisitions, including Cidara Therapeutics for $9.2 billion and Verona Pharma for around $10 billion, aimed at bolstering its pipeline ahead of Keytruda's patent expiration in 2028 [28][30] - The company is positioned to launch approximately 20 new vaccines and drugs in the coming years, with several having blockbuster potential [27][34] Market Position and Valuation - Merck's stock has increased by 9.4% over the past year, underperforming the industry average of 16.1% [20][34] - The company's shares trade at a forward P/E ratio of 15.62, lower than the industry average of 18.18, but above its five-year mean of 12.48 [23][34] Investment Considerations - While Keytruda remains a significant revenue driver, there are concerns about Merck's reliance on this drug and its ability to diversify its product lineup [31][34] - Short-term investors may be cautious due to challenges such as Gardasil's performance, potential competition for Keytruda, and rising pressures from generics [34]

Core Viewpoint - EQT Corporation is a leading U.S. natural gas production company with a market cap of $34.9 billion, primarily operating in the Appalachian Basin, focusing on the Marcellus and Utica Shales [1] Performance Summary - EQT has underperformed the broader market over the past year, with stock prices increasing by 11.3% compared to the S&P 500 Index's 16.3% gains [2] - Over the past six months, EQT's stock surged 6.1%, while the S&P 500 Index rallied by 9.4% [2] - EQT also lagged behind the Energy Select Sector SPDR Fund's (XLE) gains of 12.6% over the past 52 weeks and 13.6% over the past six months [3] Recent Developments - On January 21, EQT shares rose more than 6% due to a rally in U.S. natural gas stocks, driven by a 24% surge in natural gas prices to a six-week high [4] - For FY2025, analysts expect EQT to deliver an adjusted EPS of $2.90, reflecting an 80.1% year-over-year increase [4] - EQT has a strong track record of earnings surprises, surpassing bottom-line estimates in each of the past four quarters [4] Analyst Ratings - Among 27 analysts covering EQT, the consensus rating is a "Strong Buy," consisting of 20 "Strong Buys," one "Moderate Buy," five "Holds," and one "Strong Sell" [5] - Stephens & Co. lowered its price target on EQT to $68 from $69 but maintained an "Overweight" rating [6] - The mean price target for EQT is $64.32, indicating a 14.2% upside potential, while the highest target of $76 represents a 34.9% premium to current price levels [6]

With an impressive market cap of $64.6 billion, Emerson Electric Company (EMR) is a global technology and engineering company based in Missouri. It offers innovative solutions across industrial, commercial, and residential markets through Final Control, Measurement & Analytical, Discrete Automation, Safety & Productivity, Control Systems & Software, and Test & Measurement segments. Shares of this industrial heavyweight have outperformed the broader market over the past year. EMR has soared 17% over this ...

Core Viewpoint - Annaly Capital Management is a significant entity in the REIT sector, focusing on mortgage-backed securities, with recent financial performance showing strong earnings but challenges in revenue expectations [1][2][3]. Financial Performance - Annaly reported quarterly earnings of $0.74 per share, exceeding the Zacks Consensus Estimate of $0.72, marking a +3.25% earnings surprise and an improvement from $0.72 per share in the same quarter last year [2]. - The company reported revenues of $366.58 million for the quarter ending December 2025, which fell short of the Zacks Consensus Estimate by 21.84%, although this represents a significant increase from $187.29 million in revenues from the same period last year [3]. Stock Performance - Currently, NLY's stock is priced at $23.84, reflecting a decrease of 1.69% or $0.41, with a trading range between a low of $23.72 and a high of $24.25 during the day [4]. - Over the past year, NLY has reached a high of $24.52 and a low of $16.60, with a market capitalization of approximately $16.28 billion and a trading volume of 4,775,668 shares on the NYSE [4]. Analyst Ratings - On January 29, 2026, Wells Fargo maintained an "Overweight" rating for NLY, with a "hold" action, and raised its price target from $23 to $25 [1].

Core Viewpoint - The market anticipates a year-over-year decline in earnings for WEC Energy Group despite an increase in revenues, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - WEC Energy is expected to report quarterly earnings of $1.38 per share, reflecting a year-over-year decrease of 3.5%, while revenues are projected to be $2.45 billion, an increase of 7.2% from the previous year [3]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating that analysts have not significantly altered their initial projections [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that the Most Accurate Estimate for WEC Energy is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +0.58%, suggesting a bullish outlook from analysts [11]. Historical Performance - In the last reported quarter, WEC Energy exceeded the expected earnings of $0.79 per share by delivering $0.83, achieving a surprise of +5.06%. Over the last four quarters, the company has beaten consensus EPS estimates three times [12][13]. Investment Considerations - While WEC Energy is viewed as a strong candidate for an earnings beat, other factors may also influence stock performance, making it essential for investors to consider a comprehensive analysis before making investment decisions [14][16].

The market expects Xcel Energy (XEL) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be release ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Estee Lauder (EL) reports results for the quarter ended December 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on February 5. ...

The market expects Asbury Automotive Group (ABG) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to ...